News & Events

Attend StageBio’s Webinar on Evolution of AI and Digitization in Precision Pathology and Image Analysis

StageBio team is hosting a webinar on “Evolution of AI and Digitization in Precision Pathology and Image Analysis” on November 10, 10amEST 2023.  

This complimentary webinar is presented by Dr. Thomas Lemarchand, DVM, DESV-AP, PhD, DECVP, Director, Digital & Quantitative Pathology from StageBio and Dr. Derick Vollmer, Digital Pathology Manager, StageBio.

Attendees can expect to learn about the key milestones in the digital implementation of pathology within the chemistry, pharma and biotech industries, the current status and future of digital pathology in chemistry, pharmaceuticals, and biotechnology, the potential of digital pathology in diagnosing common lesions in toxicology studies, and more.

This webinar is perfect for research scientists, toxicologists, pathologists and lab managers in pharma/biotechnology, clinical R&D scientists, MD Pharmacists and Principal Investigators in clinical research, those interested in spatial biology and precision pathology in research and diagnosis, and computer IT, imaging scientists, image analysts and specialists.

Sign up and gain insights into an overview of the advancements in AI and image analysis (AI/IA) applications and AI and digitization in precision pathology to aid in drug discovery in the pharma, chemical and biotech sectors, with concrete examples and perspectives from a pathology-centered, tissue-based, mid-sized clinical research organization.

If you are unable to attend, sign up and receive the recording after the event.  

About Dr. Thomas Lemarchand, Director, Digital and Quantitative Pathology, StageBio

Thomas Lemarchand is a European College of Veterinary Pathology board-certified French Toxicologic, Experimental and Comparative Pathologist with 30 years of experience. Thomas started his career as a diagnostician and research Immuno-Pathologist in the United States and received his PhD from Louisiana State University in 2000. He then joined the biopharmaceutical industry in Europe as a Research and Regulatory Safety Pathologist in Servier then Eli Lilly & Company. Thomas moved to contract research organizations in 2007 to develop tissue cross-reactivity and immunohistochemistry/in situ hybridization assays and has contributed to hundreds of studies. Thomas is currently embracing and leading the digital revolution in pathology at StageBio and specializes in in situ molecular techniques and investigative/efficacy studies in animal models out of TPL Path Labs GmbH, a StageBio company, based in Freiburg, Germany. Thomas helps clients design the best possible clinical and non-clinical efficacy or safety investigative studies and is leading the implementation of in situ molecular assays and quantitative pathology projects with specialized image analysis, along with performing pathology evaluations.

About Dr Derick Vollmer. Digital Pathology Manager, StageBio

Derick Vollmer has been working in imaging and image analysis at StageBio for over 10 years. He started with StageBio as an Imaging Specialist, followed by his role as a Morphometrist for many years and now manages their digital pathology initiatives while still performing various imaging and image analysis tasks alongside their growing team.


About StageBio

StageBio is a leading provider of GLP-compliant necropsy, histology, pathology, and specimen archiving services for the biopharmaceutical, medical device, academic, and contract research industries. The company operates four GLP laboratories as well as three GLP specimen archiving facilities in the U.S., along with one GLP laboratory in Europe. We will continue to make investments in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 30+ board-certified veterinary pathologists and more than 100 laboratory technicians on staff supporting our unified commitment to quality, scientific integrity, and client satisfaction. Learn more at

Back to Index

Learn more about StageBio’s COVID-19 response